

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Security Agreement

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
MDRNA, INC.		12/22/2009	CORPORATION: DELAWARE
MDRNA Research, Inc.		12/22/2009	CORPORATION: DELAWARE
Nastech Pharmaceutical Company, Inc.		12/22/2009	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

Name:	EOS Holdings LLC, as agent
Street Address:	1068 East Main Street
City:	Ventura
State/Country:	CALIFORNIA
Postal Code:	93001
Entity Type:	LIMITED LIABILITY COMPANY: NEVADA

**PROPERTY NUMBERS Total: 5**

Property Type	Number	Word Mark
Serial Number:	77167387	MDRNA
Serial Number:	77300471	MDRNA
Serial Number:	77300487	MDRNA
Serial Number:	77300514	MDRNA
Serial Number:	77300531	

**CORRESPONDENCE DATA**

Fax Number: (866)459-2899  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 212-326-0435  
 Email: john.flynn@federalresearch.com  
 Correspondent Name: Margaret Mitchell  
 Address Line 1: 7 Times Square  
 Address Line 2: Pryor Cashman LLP

CH \$140.00 77167387

**900150916**

**TRADEMARK  
 REEL: 004121 FRAME: 0896**

Address Line 4: New York, NEW YORK 10036

NAME OF SUBMITTER:

John Flynn

Signature:

/JF/

Date:

12/29/2009

**Total Attachments: 64**

source=448828#page1.tif  
source=448828#page2.tif  
source=448828#page3.tif  
source=448828#page4.tif  
source=448828#page5.tif  
source=448828#page6.tif  
source=448828#page7.tif  
source=448828#page8.tif  
source=448828#page9.tif  
source=448828#page10.tif  
source=448828#page11.tif  
source=448828#page12.tif  
source=448828#page13.tif  
source=448828#page14.tif  
source=448828#page15.tif  
source=448828#page16.tif  
source=448828#page17.tif  
source=448828#page18.tif  
source=448828#page19.tif  
source=448828#page20.tif  
source=448828#page21.tif  
source=448828#page22.tif  
source=448828#page23.tif  
source=448828#page24.tif  
source=448828#page25.tif  
source=448828#page26.tif  
source=448828#page27.tif  
source=448828#page28.tif  
source=448828#page29.tif  
source=448828#page30.tif  
source=448828#page31.tif  
source=448828#page32.tif  
source=448828#page33.tif  
source=448828#page34.tif  
source=448828#page35.tif  
source=448828#page36.tif  
source=448828#page37.tif  
source=448828#page38.tif  
source=448828#page39.tif  
source=448828#page40.tif  
source=448828#page41.tif  
source=448828#page42.tif  
source=448828#page43.tif  
source=448828#page44.tif  
source=448828#page45.tif

**TRADEMARK**  
**REEL: 004121 FRAME: 0897**

source=448828#page46.tif  
source=448828#page47.tif  
source=448828#page48.tif  
source=448828#page49.tif  
source=448828#page50.tif  
source=448828#page51.tif  
source=448828#page52.tif  
source=448828#page53.tif  
source=448828#page54.tif  
source=448828#page55.tif  
source=448828#page56.tif  
source=448828#page57.tif  
source=448828#page58.tif  
source=448828#page59.tif  
source=448828#page60.tif  
source=448828#page61.tif  
source=448828#page62.tif  
source=448828#page63.tif  
source=448828#page64.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement"), dated as of December 22, 2009, is made by MDRNA, INC., a Delaware corporation ("MDRNA"), and MDRNA RESEARCH, INC., a Delaware corporation ("Research" and, collectively with MDRNA, "Grantors" and each, individually, "Grantor"), in favor of EOS HOLDINGS LLC, as agent (in such capacity, together with its successors and permitted assigns, the "Agent") for the Purchasers (as defined in the Security Agreement referred to below).

### W I T N E S S E T H:

**WHEREAS**, pursuant to that certain Note and Warrant Purchase Agreement, dated as of even date herewith (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "Purchase Agreement"), among Grantors and the Purchasers from time to time party thereto (the "Purchasers"; the Agent and Purchasers being collectively referred to as the "Secured Parties"), the Purchasers have severally agreed to make extensions of credit to the Grantors upon the terms and subject to the conditions set forth therein; and

**WHEREAS**, in order to induce the Purchasers to enter into the Purchase Agreement and other Transaction Documents and to induce the Purchasers to purchase the Notes as provided for in the Purchase Agreement, Grantors have agreed to pledge the Collateral to Agent, on behalf of itself and the Purchasers in accordance herewith;

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained, and to induce the Purchasers to enter into the Purchase Agreement and to induce the Purchasers to make their respective purchases of the Notes issued by the Grantors thereunder, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Security Agreement (the "Security Agreement") dated as of even date herewith among the Agent, the Purchasers and the Grantors.

Section 2. Grant of Security Interest in Intellectual Property Collateral. (A) Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations hereby mortgages, pledges, assigns, grants and hypothecates to the Agent for the benefit of the Purchasers, and grants to the Agent for the benefit of the Purchasers a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor whether now owned or hereafter acquired or arising and wherever located (the "Intellectual Property Collateral"):

(a) all of its copyrights and rights under any written agreement granting any right to use copyrights, including, without limitation, those referred to on Schedule 1 hereto, together with all renewals, reversions and extensions of the foregoing;

(b) all of its patents and rights under any written agreement granting any right to use patents, including, without limitation, those referred to on Schedule 1 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(c) all of its trademarks and rights under any written agreement granting any right to use trademarks, including, without limitation, those referred to on Schedule 1 hereto, together with all renewals, reissues, continuations and extensions of the foregoing;

(d) all goodwill of the business connected with the use of, and symbolized by, each such trademark; and

(e) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

(B) This Intellectual Property Security Agreement and the security interests created hereby secure the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Intellectual Property Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent or the Purchasers, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

Section 3. Purchase Agreement & Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with, and in no way limiting, the security interest granted to the Agent pursuant to the Security Agreement, and each Grantor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Authorization to Supplement. If any Grantor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Intellectual Property Security Agreement shall automatically apply thereto. Grantors shall give prompt (and in any event within fifteen (15) Business Days) notice in writing to Agent with respect to any such new patent rights. Without limiting Grantors' obligations under this Section 4, Grantors hereby authorize Agent on behalf of the Secured Parties unilaterally to modify this Agreement by amending Schedule I to include any such new patent rights of Grantors. Notwithstanding the foregoing, no failure to so modify this Intellectual Property Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's and the Secured Parties' continuing Security Interest in all Collateral, whether or not listed on Schedule I.

Section 5. Grantor Remains Liable. Grantors hereby agree that, anything herein to the contrary notwithstanding, Grantors shall retain full and complete responsibility for the

prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.


Section 6. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 7. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**GRANTORS:**


**MDRNA, INC.,** a Delaware corporation

By: 

Name: J. MICHAEL FRENCH

Title: PRESIDENT & CEO

**MDRNA RESEARCH, INC.,** a Delaware corporation

By: 

Name: J. MICHAEL FRENCH

Title: PRESIDENT

ACCEPTED AND AGREED  
as of the date first above written:

**EOS HOLDINGS LLC, As Agent**

By: \_\_\_\_\_


Name:

Title:

Acknowledgment of Grantors

STATE OF Washington  
COUNTY OF Snohomish ) ss

On this 21<sup>st</sup> day of December 2009, before me personally appeared J. Michael French, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of **MDRNA, INC.**, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.



Taryn Joy Frazier  
Notary Public  
*My appointment expires March 29, 2013*

STATE OF Washington  
COUNTY OF Snohomish

On this 21<sup>st</sup> day of December 2009, before me personally appeared J. Michael French, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of **MDRNA RESEARCH, INC.**, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.



Taryn Joy Frazier  
Notary Public  
*My appointment expires March 29, 2013*



IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**GRANTORS:**

**MDRNA, INC.**, a Delaware corporation

**MDRNA RESEARCH, INC.**, a Delaware corporation

By: \_\_\_\_\_

By: \_\_\_\_\_

Name: \_\_\_\_\_


Name: \_\_\_\_\_

Title: \_\_\_\_\_

Title: \_\_\_\_\_

ACCEPTED AND AGREED  
as of the date first above written:

**EOS HOLDINGS LLC, As Agent**

By:  \_\_\_\_\_  
Name: JON CARNES  
Title: MANAGING MEMBER

INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**Schedule I  
to  
Intellectual Property Security Agreement**


**REGISTERED COPYRIGHTS**

None.

**COPYRIGHT APPLICATIONS**



None.

### Trademark Registrations/Applications

Grantor	Country	Mark	Application/ Registration No.	Reg Date
MDRNA, Inc.	US	MDRNA (Standard Characters)	77/167,387	
MDRNA, Inc.	Canada	MDRNA (Standard Characters)	1368460	
MDRNA, Inc.	India	MDRNA (Standard Characters)	1614235	
MDRNA, Inc.	Israel	MDRNA (Standard Characters)	205091	
MDRNA, Inc.	Mexico	MDRNA (Standard Characters)	891845/ 1027712	2/28/2008
MDRNA, Inc.	New Zealand	MDRNA (Standard Characters)	778309/ 778309	4/24/2008
MDRNA, Inc.	Madrid Protocol (EM, IS, JP, NO, KR, RU, ES, CH, UA)	MDRNA (Standard Characters)	A0010074	10/24/2007
MDRNA, Inc.	US	MDRNA (stylized w/o color claim)  <b>MDRNA</b>	77/300,471	
MDRNA, Inc.	US	MDRNA (stylized in design w/o color claim), polymer and circle design  	77/300,487	
MDRNA, Inc.	Israel	MDRNA (stylized in design w/o color claim), polymer and circle design	210204	
MDRNA, Inc.	India	MDRNA (stylized in design w/o color claim), polymer and circle design	1673113	
MDRNA, Inc.	Mexico	MDRNA (stylized in design w/o color claim), polymer and circle design	924801/ 1050522	7/18/2008
MDRNA, Inc.	Canada	MDRNA (stylized in design w/o color claim), polymer and circle design	1390066	
MDRNA, Inc.	New Zealand	MDRNA (stylized in design w/o color claim), polymer and circle design	787232	
MDRNA, Inc.	European Community	MDRNA (stylized in design w/o color claim), polymer and circle design	6857461	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0906**

MDRNA, Inc.	Madrid Protocol (AU, IS, JP, NO, KR, RU, ES, CH, UA)	MDRNA (stylized in design w/o color claim), polymer and circle design	A0012042/ 964650	4/10/2008
MDRNA, Inc.	US	MDRNA (stylized in design w/ color claim), polymer and circle design 	77/300,514	
MDRNA, Inc.	US	(design w/o color claim) polymer design 	77/300,531	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0907**

(certain of following trademarks may have been abandoned or transferred, or not fully prosecuted)

NPCI-0366 719-20	ILEAL B Trademark	US	73/831,647	10/16/1989	
NPCI-0367 719-19 US	PRO-GESIC Trademark	US	73/833,103	10/23/1989	1,635, 254
NPCI-0369 719-24	N and Design Trademark	US	74/053,535	04/27/1990	
NPCI-0370 719-23	NASTECH and DESIGN Trademark	US	74/062,719	05/25/1990	
NPCI-0557 NPCI-0557	METHOD FOR MAKING SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	US	299842	09/01/1994	55038 52
T06-01US	NASTECH PHARMACEUTICAL COMPANY INC. (in Design, w/ Color Claim) Trademark	US	78/960,995	8/25/2006	
T06-02US	NASTECH PHARMACEUTICAL COMPANY INC. (in Design, No Color Claim) Trademark	US	78/961,002	8/25/2006	
T06-02CTM	NASTECH PHARMACEUTICAL COMPANY INC. and DESIGN (Black and White) Trademark	European Community	6443014	11/1/2007	
T06-03US	NASTECH (Stylized in Color) Trademark	US	78/962,843	8/29/2006	
T06-04US	NASTECH (Standard Characters) Trademark	US	78/962,854	8/29/2006	
T06-04CA	NASTECH (word only) Trademark	Canada	1378322	1/8/2008	
T06-04IL1	NASTECH (word only) Trademark	Israel	208498	2/18/2008	
T06-04IL2	NASTECH (word only) Trademark	Israel	208497	2/18/2008	
T06-04IN	NASTECH (word only) Trademark	India			
T06-04NZ	NASTECH (Standard Characters) Trademark	New Zealand	778504	10/26/2007	
T06-04MX1	NASTECH (Standard Characters) in IC 005 Trademark	Mexico	902691	12/17/2007	
T06-04MX2	NASTECH (Standard Characters) in IC 042 Trademark	Mexico	902696	12/17/2007	
T06-04CTM	NASTECH (Standard Characters) Trademark	European Community	6442991	11/1/2007	
T06-04MP	NASTECH (standard characters) – includes European Community (EM); Iceland (IS); Japan (JP); Norway (NO); Rep. of Korea (KR); Russia (RU); Switzerland (CH); Ukraine (UA) Trademark	Madrid Protocol	A0009888	10/10/2007	
T06-04AU	NASTECH (standard characters) Trademark	Australia	1211348	10/10/2007	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0908**

## APP. SERIAL #

DOCKET #	FILING DATE (FD) EARLIEST PRIORITY DATE (EPD)	PRIORITY DOCUMENTS	TITLE	STATUS CATEGORY
03-10P1	U.S. 60/497,740 FD: 8/25/2003 EPD: N/A	N/A	NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND STABLE DOUBLE-STRANDED RNA	Expired CM-RC
03-10CIP	U.S. 11/219,625 FD: 9/2/2005 EPD: 8/25/2003	U.S. 60/497,740 U.S. 10/925,314	DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES HAVING RIBOTHYMIDINE	Pending CM-RC
03-10CIP-PCT	PCT/US2006/020627 FD: 5/25/2006 EPD: 9/2/2005	U.S. 11/219,625 U.S. 11/219,582 U.S. 60/720,072 U.S. 11/361,793 U.S. 60/796,274	MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES	National Stage Entry CM-RC
03-10PCT	PCT/US2004/027806 FD: 8/25/2003 EPD: 8/25/2003	U.S. 60/497,740	NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND STABLE DOUBLE-STRANDED RNA	National Stage Entry D
03-10US2	U.S. 12/065,604 FD: 3/3/2008 EPD: 9/23/2005	U.S. 60/720,072 PCT/US2006/020627	MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES	Pending CM-RC
03-12P1	U.S. 60/515,533 FD: 10/29/2003 EPD: N/A	N/A	PHAGE DISPLAY TRP CAGE LIGANDS	Expired D
03-12CON	U.S. 11/955,207 FD: 12/12/2007 EPD: 10/29/2003	U.S. 60/515,533 U.S. 7,329,725	PHAGE DISPLAYED TRP CAGE LIGANDS	Pending D
03-12US	U.S. 7,329,725 FD: 10/29/2004 EPD: 10/29/2003	U.S. 60/515,533	PHAGE DISPLAYED TRP CAGE LIGANDS	Issued D
04-02P1	U.S. 60/564,543 FD: 4/20/2004 EPD: N/A	N/A	CONJUGATION OF A CHOLESTEROL MOIETY TO DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID	Expired D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

TRADEMARK  
REEL: 004121 FRAME: 0909

04-02CON	U.S. 12/013,274 FD: 1/11/2008 EPD: 4/20/2004	U.S. 11/107,371 U.S. 60/564,543	METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS	Pending D
04-02PCT	PCT/US2005/012653 FD: 4/15/2005 EPD: 4/20/2004	U.S. 60/564,543	METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS	National Stage Entry D
04-03P1	U.S. 60/568,027 FD: 5/4/2004 EPD: N/A	N/A	HISTONES COMPLEXED OR COVALENTLY BONDED TO DOUBLE-STRANDED RNA OR TO AN RNA/DNA HYBRID	Expired D
04-03CIP	U.S. 11/223,699 FD: 9/8/2005 EPD: 5/4/2004	U.S. 11/121,566 U.S. 60/667,833 U.S. 60/565,572 U.S. 60/613,416 U.S. 60/570,513 U.S. 60/570,512 U.S. 60/568,027	PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF RIBONUCLEIC ACID TO A CELL	Pending D
04-03CIP-PCT	PCT/US2006/034859 FD: 9/8/2006 EPD: 9/8/2005	U.S. 60/733,664 U.S. 60/727,216 U.S. 11/223,699	PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF RIBONUCLEIC ACID TO A CELL	National Stage Entry D
04-03PCT	PCT/US2005/015574 FD: 5/4/2005 EPD: 5/4/2004	U.S. 60/568,027 U.S. 60/570,512 U.S. 60/570,513 U.S. 60/613,416 U.S. 60/656,572 U.S. 60/667,833	COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF NUCLEIC ACIDS INTO CELLS AND FOR MODIFYING EXPRESSION OF TARGET GENES IN CELLS	National Stage Entry D
04-03CON	U.S. 12/206,165 FD: 9/8/2008 EPD: 5/4/2004	U.S. 11/121,566 U.S. 60/667,833 U.S. 60/565,572 U.S. 60/613,416 U.S. 60/570,513 U.S. 60/570,512 U.S. 60/568,027	COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF NUCLEIC ACIDS INTO CELLS AND FOR MODIFYING EXPRESSION OF TARGET GENES IN CELLS	Pending D
04-05P1	U.S. 60/570,513 FD: 5/12/2004 EPD: N/A	N/A	POLYPEPTIDES COMPLEXED OR COVALENTLY BONDED TO DOUBLE-STRANDED RNA OR RNA/DNA HYBRID	Expired D
04-06P1	U.S. 60/570,512 FD: 5/12/2004 EPD: N/A	N/A	POLYPEPTIDES COMPLEXED OR LINKED TO DOUBLE-STRANDED RNA OR TO AN RNA/DNA HYBRIDE WITH A CATIONIC LIPID	Expired D

4-17P1	U.S. 60/613,416 FD: 9/27/2004 EPD: N/A	N/A	THE USE OF RNA INTERFERENCE TO TREAT RHEUMATOID ARTHRITIS	Expired GF-TI
04-17P2	U.S. 60/667,833 FD: 4/1/2005 EPD: N/A	N/A	COMPOSITIONS AND METHODS FOR RNA INTERFERENCE TO TREAT RHEUMATOID ARTHRITIS	Expired GF-TI
04-17PCT	PCT/US2005/035259 FD: 9/27/2005 EPD: 9/27/2004	U.S. 11/121,566 U.S. 60/667,833 U.S. 60/656,572 U.S. 60/613,416	METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID	National Stage Entry GF-TI
04-17US	U.S. 11/576,139 FD: 3/27/2007 EPD: 9/27/2004	PCT/US2005/035259 U.S. 11/223,699 U.S. 11/121,566 U.S. 60/667,833 U.S. 60/656,572 U.S. 60/613,416	METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID	Pending GF-TI
05-01P1	U.S. 60/656,572 FD: 2/25/2005 EPD: N/A	N/A	CONJUGATION OR COMPLEXATION OF A PROTEIN TRANSDUCTION DOMAIN AND FUSOGENIC POLYPEPTIDE TO A SMALL INTERFERING NUCLEIC ACID FOR FOR USE IN RNA INTERFERENCE	Expired D
05-13P1	U.S. 60/720,072 FD: 9/23/2005 EPD: N/A	N/A	CHEMICALLY MODIFIED DOUBLE-STRANDED RIBONUCLEIC ACIDS AND PEPTIDES	Expired CM-RC
05-16P1	U.S. 60/727,216 FD: 10/14/2005 EPD: N/A	N/A	PEPTIDE-MEDIATED SIRNA UPTAKE INTO CELLS	Expired D
05-17P1	U.S. 60/733,664 FD: 11/4/2005 EPD: N/A	N/A	PEPTIDE MEDIATED CELLULAR UPTAKE OF DOUBLE STRANDED RNA	Expired D
05-20P1	U.S. 60/733,665 FD: 11/4/2005 EPD: N/A	N/A	PEPTIDE-DICER SUBSTRATE RNA CONJUGATES AS DELIVERY VEHICLES FOR SIRNA	Expired D
05-20PCT	PCT/US2006/042978 FD: 11/3/2006 EPD: 11/4/2005	U.S. 60/733,665	PEPTIDE-DICER SUBSTRATE RNA CONJUGATES AS DELIVERY VEHICLES FOR SIRNA	National Stage Entry D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0911**



05-25P1	U.S. 60/669,942 FD: 4/8/2005 EPD: N/A	N/A	ANTI-VIRAL COMPOSITIONS AND METHODS OF USE THEREOF	Expired GF-TI
05-25US	U.S. 11/910,971 FD: 10/8/2007 EPD: 4/8/2005	PCT/US2006/013374 U.S. 60/669,942	RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION	Pending GF-TI
05-25CIP	U.S. 11/687,564 FD: 3/16/2007 EPD: 4/8/2005	PCT/US2006/013374 U.S. 60/669,942	RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION	Pending GF-TI
06-02P1	U.S. 60/774,496 FD: 2/17/2006 EPD: N/A	N/A	PHAGE DISPLAYED CELL BINDING PEPTIDES	Expired D
06-02P2	U.S. 60/823,894 FD: 8/29/2006 EPD: N/A	N/A	PHAGE DISPLAYED CELL BINDING PEPTIDES	Expired D
06-02US	U.S. 11/627,863 FD: 1/26/2007 EPD: 2/17/2006	U.S. 60/823,894 U.S. 60/774,496	PHAGE DISPLAYED CELL BINDING PEPTIDES	Pending D
05-25PCT	PCT/US2006/013374 FD: 4/7/2006 EPD: 4/8/2005	U.S. 60/669,942	RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION	National Stage Entry GF-TI
06-11P1	U.S. 60/760,714 FD: 1/20/2006 EPD: N/A	N/A	DRY POWDER COMPOSITIONS	Expired GF-TI
06-11US	U.S. 11/623,306 FD: 1/15/2007 EPD: 1/20/2006	U.S. 60/760,714	DRY POWDER COMPOSITIONS FOR RNA INFLUENZA THERAPEUTICS	Pending GF-TI
06-14P1	U.S. 60/796,274 FD: 4/27/2006 EPD: N/A	N/A	COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX	Expired CM-RC
06-14US	U.S. 11/610,403 FD: 12/13/2006 EPD: 4/27/2006	U.S. 60/796,274	COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX	Pending CM-RC

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0912**

06-16P1	U.S. 60/798,243 FD: 5/5/2006 EPD: N/A	N/A	COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY	Expired D
06-16US	U.S. 11/743,480 FD: 5/2/2007 EPD: 5/5/2006	U.S. 60/798,243	COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY	Pending D
06-17P1	U.S. 60/747,622 FD: 5/18/2006 EPD: N/A	N/A	FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA	Expired D
06-17US	U.S. 11/750,979 FD: 5/18/2007 EPD: 5/18/2006	U.S. 60/747,622	FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA	Pending D
06-18P1	U.S. 60/821,528 FD: 8/4/2006 EPD: N/A	N/A	DEVICE FOR IMPROVED PEPTIDE DELIVERY	Expired D
06-18US	U.S. 11/774,492 FD: 7/6/2007 EPD: 8/4/2006	U.S. 60/821,528	DEVICE FOR IMPROVED PEPTIDE DELIVERY	Pending D
06-20P1	U.S. 60/803,065 FD: 5/24/2006 EPD: N/A	N/A	COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS	Expired SF-MPC
06-20US	U.S. 11/676,226 FD: 2/16/2007 EPD: 5/24/2006	U.S. 60/803,065	COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS	Pending SF-MPC
06-21P1	U.S. 60/803,175 FD: 5/25/2006 EPD: N/A	N/A	CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY	Expired D
06-21US	U.S. 11/676,221 FD: 2/16/2007 EPD: 5/25/2006	U.S. 60/803,175	CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY	Pending D
06-22P1	U.S. 60/805,327 FD: 6/20/2006 EPD: N/A	N/A	COMPOSITIONS AND METHODS FOR LIPID-BASED SIRNA INTRACELLULAR DELIVERY	Expired D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0913**

06-31P1	U.S. 60/822,896 FD: 8/18/2006 EPD: N/A	N/A	PEPTIDE-DICER SUBSTRATE RNA CONJUGATES AS DELIVERY VEHICLES FOR SIRNA	Expired D
06-31PCT	PCT/US2007/075744 FD: 8/10/2007 EPD: 8/18/2006	U.S. 60/945,868 U.S. 60/939,578 U.S. 60/822,896	DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS	Pending D
06-32P1	U.S. 60/825,878 FD: 9/15/2006 EPD: N/A	N/A	COMPOUNDS AND METHODS FOR PEPTIDE RIBONUCLEIC ACID CONDENSATE PARTICLES FOR RNA THERAPEUTICS	Expired D
06-32PCT	PCT/US2006/040174 FD: 10/13/2006 EPD: 9/15/2006	U.S. 60/825,878 U.S. 60/733,665 U.S. 60/727,216	COMPOUNDS AND METHODS FOR PEPTIDE RIBONUCLEIC ACID CONDENSATE PARTICLES FOR RNA THERAPEUTICS	National Stage Entry D
06-34P1	U.S. 60/862,027 FD: 10/18/2006 EPD: N/A	N/A	COMPOSITIONS AND METHODS EMPLOYING GAPPED OR NICKED SIRNA MOLECULES	Expired CM-RC
07-04P2	U.S. 60/910,393 FD: 4/5/2007 EPD: N/A	N/A	COMPOSITIONS AND METHODS OF USING GAPPED OR NICKED DOUBLE STRANDED NUCLEIC ACID MOLECULES	Expired CM-RC
07-04P3	U.S. 60/955,317 FD: 8/10/2007 EPD: N/A	N/A	COMPOSITIONS AND METHODS OF USING DOUBLE-STRANDED NUCLEIC ACID MOLECULES CONTAINING ONE OR MORE GAP OR NICK	Expired CM-RC
07-04P4	U.S. 60/969,136 FD: 8/30/2007 EPD: N/A	N/A	COMPOSITIONS AND METHODS OF USING DOUBLE-STRANDED NUCLEIC ACID MOLECULES CONTAINING ONE OR MORE GAP OR NICK	Expired CM-RC
07-04PCT	PCT/US2007/081836 FD: 10/18/2007 EPD: 10/18/2006	U.S. 60/969,136 U.S. 60/955,317 U.S. 60/910,393 U.S. 60/862,027	NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF	National Stage Entry CM-RC
07-10P1	U.S. 60/916,131 FD: 5/4/2007 EPD: N/A	N/A	AMINO ACID LIPID COMPOSITIONS AND METHODS FOR DELIVERING RNA THERAPEUTICS	Expired D

07-10P2	U.S. 60/947,282 FD: 6/29/2007 EPD: N/A	N/A	AMINO ACID LIPID COMPOSITIONS AND METHODS FOR DELIVERING RNA THERAPEUTICS	Expired D
07-10P3	U.S. 60/953,667 FD: 8/2/2007 EPD: N/A	N/A	AMINO ACID LIPID COMPOSITIONS AND METHODS FOR DELIVERING RNA THERAPEUTICS	Expired D
07-10P4	U.S. 60/972,653 FD: 9/14/2007 EPD: N/A	N/A	AMINO ACID LIPIDS AND USES FOR RNA THERAPEUTICS	Expired D
07-10PCT	PCT/US2008/62526 FD: 5/2/200 EPD: 5/4/2007	U.S. 60/972,653 U.S. 60/953,667 U.S. 60/947,282 U.S. 60/916,131	AMINO ACID LIPIDS AND USES THEREOF	National Stage Entry D
07-10US	U.S. 12/114,284 FD: 5/2/200 EPD: 5/4/2007	U.S. 60/972,653 U.S. 60/953,667 U.S. 60/947,282 U.S. 60/916,131	AMINO ACID LIPIDS AND USES THEREOF	Pending D
07-15P1	U.S. 60/972,590 FD: 9/14/2007 EPD: N/A	N/A	EMULSION COMPOSITIONS FOR INTERFERING RNA AND USES THEREOF	Expired D
07-17P1	U.S. 60/955,314 FD: 8/10/2007 EPD: N/A	N/A	RNA THERAPEUTICS FOR DRUG RESISTANT INFLUENZA	Expired GF-TI
07-17P2	U.S. 60/979,772 FD: 10/12/2007 EPD: N/A	N/A	USES OF BROAD SPECTRUM RNAI THERAPEUTICS AGAINST INFLUENZA	Pending GF-TI
07-17US	U.S. 12/189,563 FD: 8/11/2008 EPD: 8/10/2007	U.S. 60/979,772 U.S. 60/955,314	USES OF BROAD SPECTRUM RNAI THERAPEUTICS AGAINST INFLUENZA	Pending GF-TI
07-21P1	U.S. 61/022,571 FD: 1/22/2008 EPD: N/A	N/A	DISPERSION COMPOSITIONS FOR INTERFERING RNA AND USES THEREOF	Pending D
07-23P1	U.S. 60/976,894 FD: 10/2/2007 EPD: N/A	N/A	LIPOPEPTIDES FOR DELIVERY OF INTERFERING RNA AGENTS	Expired D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0915**

07-23PCT	PCT/US2008/078627 FD: 10/2/2008 EPD: 10/2/2007	U.S. 60/976,894	LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS	Pending D
07-R001P1	U.S. 60/934,940 FD: 3/2/2007 EPD: N/A	N/A	COMPOUNDS FOR INHIBITING TNF GENE EXPRESSION BY RIBONUCLEIC ACID INTERFERENCE AND USES THEREOF	Abandoned GF-TI
07-R002P1	U.S. 60/934,930 FD: 3/16/2007 EPD: N/A	N/A	COMPOUNDS FOR INHIBITING GENE EXPRESSION BY RIBONUCLEIC ACID INTERFERENCE AND USES THEREOF	Expired GF-TI
07-R004P1	U.S. 60/934,931 FD: 4/20/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R004US	U.S. 12/039,650 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,931 U.S. 60/934,934 U.S. 60/934,928 U.S. 60/934,943 U.S. 60/934,942	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R007P1	U.S. 60/934,928 FD: 4/24/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGFB GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R009P1	U.S. 60/934,943 FD: 4/25/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING FIGF GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R010P1	U.S. 60/934,934 FD: 4/24/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING PGF GENE EXPRESSION AND USES THEREOF	Expired GF-TI

07-R011P1	U.S. 60/932,949 FD:5/03/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R011PCT	PCT/US2008/055380 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,931 U.S. 60/934,934 U.S. 60/934,928 U.S. 60/934,943 U.S. 60/932,949	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R011US	U.S. 12/528,508 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,931 U.S. 60/934,934 U.S. 60/934,928 PCT/US2008/055380	NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R013P1	U.S. 60/934,945 FD:5/10/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING EGFR GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R013US	U.S. 12/039,658 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,946 U.S. 60/934,945 U.S. 60/934,935 U.S. 60/934,922	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R014P1	U.S. 60/934,946 FD:5/03/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB2 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R015P1	U.S. 60/934,935 FD:5/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB3 GENE EXPRESSION AND USES THEREOF	Expired GF-TI

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0917**

07-R016P1	U.S. 60/934,922 FD:5/17/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB4 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R017P1	U.S. 60/932,970 FD:5/22/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R017PCT	PCT/US2008/055360 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,946 U.S. 60/934,945 U.S. 60/934,935 U.S. 60/934,922 U.S. 60/932,970	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R017US	U.S. 12/528,619 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/934,946 U.S. 60/934,945 U.S. 60/934,935 U.S. 60/934,922 U.S. 60/932,970 PCT/US2008/055360	NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R037P1	U.S. 60/956,093 FD:8/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R037PCT	PCT/US2008/055385 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/956,093	NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI

07-R037US	U.S. 12/528,786 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/956,093 PCT/US2008/055385	NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R044P1	U.S. 60/973,397 FD:9/18/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING RAF1 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R045P1	U.S. 60/973,398 FD:9/18/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT1 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R045PCT	PCT/US2008/055339 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/973,398 U.S. 60/013,212 U.S. 60/013,239 U.S. 60/973,397	NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R045US	U.S. 12/039,662 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/973,398 U.S. 60/013,212 U.S. 60/013,239 U.S. 60/973,397	NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R046P1	U.S. 61/013,212 FD:12/12/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT2 GENE EXPRESSION AND USES THEREOF	Expired GF-TI

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0919**



07-R047P1	U.S. 61/013,239 FD:12/12/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING AKT3 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R060P1	U.S. 60/989,419 FD:11/20/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R060PCT	PCT/US2008/055515 FD: 2/29/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/989,419	NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R060US	U.S. 12/529,011 FD: 2/29/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/989,419 PCT/US2008/055515	NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R071P1	U.S. 60/988,395 FD:11/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R071PCT	PCT/US2008/55615 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/988,395	NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R071US	U.S. 12/529,138 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/988,395 PCT/US2008/55615	NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF	Pending GF-TI

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0920**

07-R075P1	U.S. 60/988,400 FD:11/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING NRAS GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R075PCT	PCT/US2008/055644 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/988,400 U.S. 60/988,401 U.S. 60/988,402	NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI
07-R075US	U.S. 12/529,302 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/988,400 U.S. 60/988,401 PCT/US2008/055644	NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R076P1	U.S. 60/988,401 FD:11/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING HRAS GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R077P1	U.S. 60/988,402 FD:11/15/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING KRAS GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R079P1	U.S. 61/015,611 FD:12/20/2007 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT3A GENE EXPRESSION AND USES THEREOF	Expired GF-TI
07-R079PCT	PCT/US2008/055649 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 61/015,611	NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF	National Stage Entry GF-TI

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0921**

07-R079US	U.S. 12/529,532 FD: 3/3/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 61/015,611 PCT/US2008/055649	NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R107US	U.S. 12/039,668 FD: 2/28/2008 EPD: 3/2/2007	U.S. 60/934,940 U.S. 60/934,930 U.S. 60/992,975	NUCLEIC ACID COMPOUNDS FOR INHIBITING APOB GENE EXPRESSION AND USES THEREOF	Pending GF-TI
07-R-US-CIP	U.S. 12/552,082 FD: 09/02/2009 EPD: 3/2/2007	79 PCT Patent Applications Covering over 140 Gene Targets	NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF	Pending GF-TI
08-01P1	U.S. 61/057,153 FD: 5/29/2008 EPD: N/A	N/A	LIPHILIC AMINES AND USES THEREOF	Expired D
08-01PCT	PCT/US2009/45664 FD: 5/29/2009 EPD: 5/29/2008	U.S. 61/057,153	MULTI-ARM AMINES AND USES THEREOF	Pending D
08-04P2	U.S. 61/220,247 FD: 6/25/2009 EPD: N/A	N/A	REGULATORY NUCLEIC ACIDS AND USES THEREOF	Pending CM-RC
08-06P1	U.S. 61/073,633 FD: 6/18/2008 EPD: N/A	N/A	RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF	Pending CM-RC
08-06US	U.S. 12/486,889 FD: 6/18/2009 EPD: 6/18/2008	U.S. 61/073,633	RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF	Pending CH
08-07PCT	PCT/US2008/64417 FD: 5/21/2008 EPD: 5/22/2007	PA 200800534 PA 200701785 PA 200701718 PA 200700751	HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES	Pending CM-RC

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0922**

08-07US	U.S. 12/515,403 FD: 5/21/2008 EPD: 5/22/2007	PCT/US2008/64417 PA 200800534 PA 200701785 PA 200701718 PA 200700751	HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES	Pending CO
08-09P1	U.S. 61/086,435 FD:8/5/2008 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF	Pending GF-TI
08-09PCT	PCT/US2009/052878 FD: 08/05/2009 EPD: 08/05/2008	U.S. 61/086,435	NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF	Pending GF-TI
08-10P1	U.S. 61/086,445 FD:8/5/2008 EPD: N/A	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
08-10PCT	PCT/US2009/052888 FD: 08/05/2009 EPD: 08/05/2008	U.S. 61/086,445	NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
08-16P1	U.S. 61/106,062	N/A	COMPOSITIONS AND METHODS FOR LIPOSOMAL RNA THERAPEUTICS	Pending D
08-16PCT	PCT/US2009/60930 FD:10/16/2009 EPD: 10/16/2008	U.S. 61/106,062 U.S. 61/167,379	PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS	Pending D
08-16US	U.S. 12/580,250 FD: 10/16/2009 EPD: 10/16/2008	U.S. 61/106,062 U.S. 61/167,379	PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS	Pending D
08-17P1	U.S. 61/116,258	N/A	COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	Pending D
08-17PCT	PCT/US2009/65153 FD: 11/19/2009 EPD: 11/19/2008	U.S. 61/116,258	COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE THERAPEUTICS	Pending
08-18P1	U.S. 61/141,080	N/A	COMPOSITIONS AND METHODS FOR EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS	Pending D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0923**

08-19P1	U.S. 61/119,624	N/A	RNA OLIGONUCLEOTIDES AND RNA COMPLEXES COMPRISING ACYCLIC NUCLEOMONOMERS	Pending CM-RC
08-19P2	U.S. 61/252,085 FD: 10/15/2009	N/A	RNA COMPLEXES COMPRISING ACYCLIC NUCLEOMONOMERS	Pending CO
08-19PCT	PCT/US2009/66610 FD: 12/3/2009 EPD 12/3/2008	U.S. 61/119,624 U.S. 61/252,085	UsiRNA COMPLEXES	Pending
09-01P1	U.S. 61/145,177 FD: 01/16/2009	N/A	NUCLEIC ACID COMPOUNDS FOR INHIBITING FABP FAMILY GENE EXPRESSION AND USES THEREOF	Pending GF-TI
09-02P1	U.S. 61/167,379 FD: 4/7/2009	N/A	COMPOSITIONS AND METHODS FOR EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS	Pending D
09-03P1	U.S. 61/258,115	N/A	AMINO ACID-BASED NANOPARTICLE FORMULATIONS	Pending D

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0924**

(certain of following may have been abandoned or transferred, or not fully prosecuted)

Client Case No.	Title	Country	App. No.	Filing Date	Pat. No
00-02US	BIMODAL EMULSIONS OF TAXANES AND BUTYRATE POLYALCOHOL ESTERS	US	09/631,246	08/02/2000	
00-03CIP	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS	US	11/537,468	09/29/2006	
00-03DIV	LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS	US	10/879,814	06/28/2004	
00-03PCT	COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM	PCT	PCT/US2007/061881	02/08/2007	
00-03PCT2	INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM	PCT	PCT/US2007/079994	09/28/2007	
00-03US	LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND PREVENTION OF BREAST CANCER	US	09/678,591	10/03/2000	6,894,026
00-06US	ADMINISTRATION OF APOMORPHINE FOR TREATING PREMATURE EJACULATION	US	09/644,406	08/23/2000	
01-01EP	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	EPO	02780887.2	09/22/2003	
01-01PCT	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	PCT	PCT/US2002/20171	06/24/2002	
01-01US	DOPAMINE AGONIST FORMULATIONS FOR ENHANCED CENTRAL NERVOUS SYSTEM DELIVERY	US	09/891,630	06/25/2001	
02-01AU	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Australia	2003269874	05/19/2003	
02-01CA	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Canada	2,482,161	10/12/2004	
02-01CIP	CARBOXYLATE SALTS OF GALANTAMINE AND THEIR PHARMACEUTICAL USE	US	10/831,031	04/23/2004	
02-01CIP2	COMPOSITIONS AND METHODS USING ACETYLCHOLINESTERASE (ACE) INHIBITORS TO TREAT CENTRAL NERVOUS SYSTEM (CNS) DISORDERS IN MAMMALS	US	11/112,950	04/22/2005	
02-01CIP-CA	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	Canada	2,564,353	10/10/2006	
02-01CIP-EP	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	EPO	05758604.2	11/14/2006	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0925**

02-01CIP-JP	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	Japan	2007-509671	10/20/2006	
02-01CIP-MX	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	Mexico	PA/a/2006/012269	10/23/2006	
02-01CIP-PCT	GALANTAMINE SALTS, METHOD OF PRODUCING IT AND NASAL COMPOSITION THEREOF	PCT	PCT/US2005/013776	04/22/2005	
02-01EP	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	EPO	03751761.2	11/05/2004	
02-01HK	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Hong Kong	05102306.0	03/16/2005	
02-01IL	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Israel	163731	08/25/2004	
02-01IN	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	India	1664/KOLNP/2004	11/05/2004	
02-01JP	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	Japan	2004-517563	11/22/2004	
02-01NZ	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	New Zealand	535192	05/19/2003	535192
02-01P1	CSF ADMINISTRATION OF ACE INHIBITORS	US	60/382,122	05/21/2002	
02-01PCT	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	PCT	PCT/US03/15653	05/19/2003	
02-01US	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	US	10/439,108	05/15/2003	
02-01ZA	ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO THE CEREBRAL SPINAL FLUID	South Africa	2004/7420	09/15/2004	2004/7420
02-02AU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	Australia	2003267965	11/30/2004	
02-02CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	Canada	2,486,531	06/18/2003	
02-02CON	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	US	11/953,685	12/10/2007	
02-02EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	EPO	03748913.5	01/24/2005	
02-02IL	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	Israel	165172	11/11/2004	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0926**

02-02NZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	New Zealand	536939	12/02/2004	536939
02-02P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA (IFN-BETA)	US	60/393,066	06/28/2002	
02-02PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	PCT	PCT/US03/19261	06/18/2003	
02-02US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	US	10/462,452	06/16/2003	
02-02ZA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON BETA	South Africa	2004/9652	11/29/2004	2004/965 2
02-03AU	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	Australia	2003279750	06/24/2003	
02-03CA	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	Canada	2,487,712	06/24/2003	
02-03EP	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	EPO	03742185.6	01/24/2005	
02-03IL	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	Israel	165441	11/29/2004	
02-03IN	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	India	1951/KOLNP/2004	12/17/2004	
02-03JP	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	Japan	2004-517800	12/28/2004	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0927**



02-03NZ	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	New Zealand	537569	06/24/2003	
02-03P1	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/392,512	06/28/2002	
02-03PCT	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	PCT	PCT/US03/19994	06/24/2003	
02-03US	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	10/601,953	06/24/2003	
02-03ZA	COMPOSITIONS AND METHODS FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	South Africa	2004/10287	12/21/2004	2004/10287
02-04AE	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	United Arab Emirates	320/2005	06/11/2005	
02-04AM	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Armenia			
02-04AU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Australia	2003299722	12/17/2003	
02-04AZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Azerbaijan			
02-04BB	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Barbados	2001/1146	06/09/2005	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0928**

02-04BR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Brazil	0316685-6	06/16/2005	
02-04BY	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Belarus			
02-04BZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Belize	BZ388.05	06/16/2005	
02-04CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Canada	2,510,199	12/17/2003	
02-04CIP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/745,069	12/23/2003	7,186,691
02-04CIP3	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/780,325	02/17/2004	7,229,966
02-04CIP3-CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Canada	2,555,826	08/09/2006	
02-04CIP3-EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	EPO	05723353.8	07/20/2006	
02-04CIP3-HK	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Hong Kong			
02-04CIP3-JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Japan	2006-553374	08/15/2006	
02-04CIP3-MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Mexico	PA/a/2006/009331	08/16/2006	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0929**

02-04CIP3-PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	PCT	PCT/US2005/005339	02/17/2005	
02-04CIP4	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/869,649	06/16/2004	7,186,692
02-04CN	COMPOSITIONS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND USES FOR TREATING OBESITY	China	200380106468.9	06/17/2005	
02-04CO	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Colombia	05-058.645	06/16/2005	
02-04CON2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/768,288	01/30/2004	7,157,426
02-04CON2-DIV	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE	US	11/467,509	08/25/2006	
02-04CON2-DIV2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE	US			
02-04CR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Costa Rica	6789	06/17/2005	
02-04DIV1	COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY	US	11/561,331	11/17/2006	
02-04DIV3	METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES FOR TREATING AND PREVENTING OBESITY	US	11/563,587	11/27/2006	
02-04DIV4	COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES	US	11/561,825	11/20/2006	
02-04DIV5	A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES	US	11/562,913	11/22/2006	
02-04DZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Algeria	050217	06/20/2005	050217

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0930**

02-04EA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	EAPO	200501007	07/18/2005	008829
02-04EC	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Ecuador	05-5839	06/17/2005	
02-04EG	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Egypt	2005/06/306	06/16/2005	
02-04EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	EPO	03800002.2	12/17/2003	
02-04GE	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Georgia	8901/01/-05	06/15/2005	
02-04HK	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Hong Kong	06102556.6	02/27/2006	
02-04ID	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Indonesia	W-00200501620	06/17/2005	W-00200501620
02-04ID-DIV	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Indonesia	W-00200800724	03/03/2008	
02-04IL	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Israel	169108	06/09/2005	
02-04IN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	India	1373/KOLNP/2005	07/15/2005	
02-04JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Japan	2005-502646	06/17/2005	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0931**

02-04KG	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Kyrgyz Republic			
02-04KR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Republic of Korea	10-2005-7009727	05/30/2005	
02-04KZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Kazakhstan			
02-04MA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Morocco	28337/2005	06/15/2005	28337
02-04MD	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Republic of Moldova			
02-04MN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Mongolia	3587	06/08/2005	2654
02-04MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PEPTIDE YY AND METHODS FOR TREATING AND PREVENTING OBESITY	Mexico	PA/a/2005/006572	06/17/2005	
02-04NI	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PEPTIDE YY AND METHODS FOR TREATING AND PREVENTING OBESITY	Nicaragua	2005-0108	06/16/2005	
02-04NO	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Norway	2005 3430	07/14/2005	
02-04NZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	New Zealand	540317	12/17/2003	
02-04OM	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Oman	PCT 56/2005	06/15/2005	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0932**

02-04PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	PCT	PCT/US03/40538	12/17/2003	
02-04PH	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Philippines	1-2005-501170	06/17/2005	
02-04RU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Russian Federation			
02-04SG	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Singapore	200503079-6	05/13/2005	112496
02-04SG2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Singapore	200703952-2	06/04/2007	
02-04TJ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Tajikistan			
02-04TM	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Turkmenistan			
02-04TN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Tunisia	05162	06/17/2005	SN05 162
02-04TT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Trinidad and Tobago	TT/A/2005/00106	08/11/2005	
02-04UA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Ukraine	200507097	07/18/2005	
02-04US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PEPTIDE YY AND METHODS FOR TREATING AND PREVENTING OBESITY	US	10/322,266	12/17/2002	7,166,575

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0933**

02-04VN	COMPOSITON FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND USE OF THESE PEPTIDES IN MANUFACTURING MEDICAMENT FOR TREATMENT AND PREVE	Viet Nam	1-2005-00953	07/11/2005	
02-04ZA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	South Africa	2005/04875	06/14/2005	2005/04875
03-01P1	METHOD AND COMPOSITIONS TO TREAT MALE INFERTILITY	US	60/444,032	01/31/2003	
03-01PCT	METHOD AND COMPOSITIONS FOR TREATING MALE INFERTILITY	PCT	PCT/US04/02400	01/27/2004	
03-05P1	INTRANASAL ADMINISTRATION OF TRIPTANS	US	60/464,671	04/22/2003	
03-05PCT	INTRANASAL ADMINISTRATION OF TRIPTANS	PCT	PCT/US2004/011445	04/14/2004	
03-05US	INTRANASAL ADMINISTRATION OF TRIPTANS	US	10/824,452	04/14/2004	
03-06P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	US	60/469,079	05/08/2003	
03-06PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	PCT	PCT/US2004/014261	05/07/2004	
03-06US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF INTERFERON ALPHA	US	10/840,536	05/06/2004	
03-07CA	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	Canada	2,523,870	10/27/2005	
03-07CN	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	China	200480018784.5	12/30/2006	
03-07EP	METHOD FOR DIAGNOSING AND TREATING CANCER	EPO	04751031.8	04/30/2004	
03-07JP	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	Japan	2006-514176	10/28/2005	
03-07MX	METHOD FOR DIAGNOSING AND TREATING CANCER	Mexico	PA/a/2005/011644	10/28/2005	
03-07NO	METHOD FOR DIAGNOSING AND TREATING CANCER	Norway	2005 5449	11/17/2005	
03-07P1	METHOD FOR DIAGNOSING AND TREATING CANCER	US	60/466,905	04/30/2003	
03-07PCT	CLAUDINS' UNDEREXPRESSION AS MARKERS OF TUMOR METASTASIS	PCT	PCT/US2004/013436	04/30/2004	
03-07US	METHOD FOR DIAGNOSING AND TREATING CANCER	US	10/836,421	04/30/2004	
03-08CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Canada	2,528,465	12/06/2005	
03-08EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	EPO	04754279.0	01/05/2006	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0934**

03-08JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Japan	2006-533559	12/08/2005	
03-08MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	Mexico	PA/a/2005/013340	12/08/2005	
03-08P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	US	60/477,403	06/09/2003	
03-08PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	PCT	PCT/US04/17632	06/01/2004	
03-08US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF GROWTH HORMONE	US	10/862,141	06/01/2004	
03-09AR	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Argentina	P04 01 02789	08/05/2004	
03-09CL	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Chile	2023-2004	08/05/2004	
03-09EG	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Egypt			
03-09MY	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Malaysia	PI 20043210	08/06/2004	
03-09P1	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/493,226	08/07/2003	
03-09P2	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/501,170	09/08/2003	
03-09P3	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/510,785	10/10/2003	
03-09P4	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/517,290	11/04/2003	
03-09P5	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	US	60/518,812	11/10/2003	
03-09PE	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Peru	754-2004	08/05/2004	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0935**



03-09SA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Saudi Arabia	04250240	08/04/2004	
03-09TW	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	Taiwan	93123699	08/06/2004	
03-09VE	PROTEIN-FREE FORMULATION OF PEPTIDE YY SUITABLE FOR INTRANASAL ADMINISTRATION	Venezuela	2004-01280	08/06/2004	
03-11P1	METHOD FOR TREATING PARKINSON'S DISEASE USING APOMORPHINE AND APOMORPHINE PRODRUGS	US	60/514,382	10/24/2003	
03-11PCT	TREATMENT OF PARKINSON'S DISEASE USING APOMORPHINE IN COMBINATION WITH AN APOMORPHINE PRODRUG	PCT	PCT/US2004/034929	10/21/2004	
03-11US	METHOD FOR TREATING PARKINSON'S DISEASE USING APOMORPHINE AND APOMORPHINE PRODRUGS	US	10/964,327	10/12/2004	
03-12CON	PHAGE DISPLAYED TRP CAGE LIGANDS	US	11/955,207	12/12/2007	
03-12P1	PHAGE DISPLAYED TRP CAGE LIGANDS	US	60/515,533	10/29/2003	
03-12US	PHAGE DISPLAYED TRP CAGE LIGANDS	US	10/976,942	10/29/2004	7,329,725
04-01P1	METHODS OF COMPARING Y2 RECEPTOR BINDING COMPOUND FORMULATIONS BY BIOEQUIVALENCE METHODS USING EXTRACTED HUMAN PLASMA	US	60/543,111	02/09/2004	
04-01PCT	METHODS FOR DETERMINING THE AMOUNT OF PEPTIDE YY IN BLOOD	PCT	PCT/US05/04168	02/09/2005	
04-01US	METHODS FOR DETERMINING THE AMOUNT OF PEPTIDE YY IN BLOOD	US	11/054,245	02/09/2005	
04-04AU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Australia	2005247369	12/08/2006	
04-04CA	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Canada	2,567,056	11/09/2006	
04-04CIP	GRAS COMPOSITION FOR INTRANASAL DELIVERY OF PARATHYROID HORMONE	US	11/246,450	10/06/2005	
04-04CIP2	METHOD OF TREATING OSTEOPOROSIS USING INTRANASAL PARATHYROID HORMONE	US	11/246,406	10/06/2005	
04-04CIP3	STABILIZED TERIPARATIDE SOLUTION	US	11/347,554	02/03/2006	
04-04CIP4	METHOD OF DELIVERING PARATHYROID HORMONE TO A HUMAN	US	11/347,551	02/03/2006	
04-04CIP5	STABLE PHARMACEUTICAL DOSAGE FORMS OF TERIPARATIDE	US	11/390,940	03/27/2006	
04-04CIP-AU	PTH FORMULATIONS AND METHODS OF USE	Australia	2006299887	04/01/2008	
04-04CIP-CA	PTH FORMULATIONS AND METHODS OF USE	Canada		04/07/2008	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0936**

04-04CIP-CN	PTH FORMULATIONS AND METHODS OF USE	China		06/05/2008	
04-04CIP-EP	PTH FORMULATIONS AND METHODS OF USE	EPO	06749687.7	03/28/2008	
04-04CIP-IL	PTH FORMULATIONS AND METHODS OF USE	Israel	190583	04/02/2008	
04-04CIP-IN	PTH FORMULATIONS AND METHODS OF USE	India	2807/DELNP/2008	04/03/2008	
04-04CIP-JP	PTH FORMULATIONS AND METHODS OF USE	Japan		04/01/2008	
04-04CIP-KR	PTH FORMULATIONS AND METHODS OF USE	Republic of Korea	10-2008-7010885	05/06/2008	
04-04CIP-MX	PTH FORMULATIONS AND METHODS OF USE	Mexico	MX/a/2008/004575	04/04/2008	
04-04CIP-NZ	PTH FORMULATIONS AND METHODS OF USE	New Zealand	567871	05/02/2008	
04-04CIP-PCT	PTH FORMULATIONS AND METHODS OF USE	PCT	PCT/US2006/013377	04/10/2006	
04-04CIP-SG	PTH FORMULATIONS AND METHODS OF USE	Singapore	200802536-3	04/01/2008	
04-04CIP-ZA	PTH FORMULATIONS AND METHODS OF USE	South Africa	2008/03974	05/05/2008	
04-04CN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	China	20050023137.8	01/09/2007	
04-04CON	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/744,745	05/04/2007	
04-04DIV1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,055	10/17/2006	
04-04DIV2	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,061	10/17/2006	
04-04DIV3	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/550,051	10/17/2006	
04-04EP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	EPO	05780065.8	12/08/2006	
04-04IN	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	India	6774/DELNP/2006	11/10/2006	
04-04JP	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Japan	2007-513324	11/08/2006	
04-04MX	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Mexico	PA/a/2006/012980	11/09/2006	
04-04NO	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Norway	2006/5673	12/08/2006	
04-04NZ	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	New Zealand	551875	12/07/2006	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0937**

04-04P1	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	60/570,113	05/10/2004	
04-04PCT	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	PCT	PCT/US2005/016530	05/10/2005	
04-04PCT3	PTH FORMULATIONS AND METHODS OF USE	PCT	PCT/2006/38735	10/03/2006	
04-04RU	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	Russian Federation	2006143544/20	12/11/2006	12/11/2006
04-04US	COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	11/126,996	05/10/2005	7,244,709
04-08AU	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Australia	2005251786	12/29/2006	
04-08CA	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Canada	2,569,137	11/29/2006	
04-08CN	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	China	200580024025.4	01/16/2007	
04-08EP	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	EPO	05757909.6	01/03/2007	
04-08IN	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	India	7041/DELNP/2006	11/23/2006	
04-08JP	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Japan	2007-515683	12/05/2006	
04-08KR	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Republic of Korea	10-2007-7000318	01/05/2007	
04-08MX	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Mexico	PA/a/2006/014215	12/06/2006	
04-08NO	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	Norway	20070072	01/04/2007	
04-08NZ	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	New Zealand	552346	01/03/2007	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0938**

04-08P1	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	US	60/577,695	06/07/2004	
04-08PCT	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	PCT	PCT/US2005/019908	06/07/2005	
04-08US	INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES	US	11/570,068	12/05/2006	
04-09P1	PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY	US	60/580,329	06/16/2004	
04-09PCT	PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS	PCT	PCT/US2005/021377	06/16/2005	
04-09US	PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS	US	11/570,223	12/07/2006	
04-10P1	PEPTIDE YY FORMULATIONS HAVING INCREASED RESISTANCE TO MICROBIAL AGENTS	US	60/580,310	06/16/2004	
04-12P1	PERMEABILIZING PEPTIDES FOR MODULATING PHYSIOLOGY OF EPITHELIAL JUNCTIONAL ADHESION MOLECULES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/586,288	07/07/2004	
04-13P1	COMPOSITIONS AND METHODS FOR INTRANASAL ADMINISTRATION OF INACTIVE ANALOGS OF PTH OR INACTIVATED PREPARATIONS OF PTH OR PTH ANALOGS	US	60/601,215	08/13/2004	
04-13US	COMPOSITIONS AND METHODS FOR INTRANASAL ADMINISTRATION OF INACTIVE ANALOGS OF PTH OR INACTIVATED PREPARATIONS OF PTH OR PTH ANALOGS	US	11/205,255	08/15/2005	
04-15P1	PERMEABILIZING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/612,121	09/21/2004	
04-15P2	PERMEABILIZING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF MACROMOLECULAR AND SMALL MOLECULE THERAPEUTIC COMPOUNDS	US	60/667,835	04/01/2005	
04-16P1	CYCLIC PERMEABILIZING PEPTIDE FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/612,285	09/21/2004	
04-16P2	PERMEABILIZING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/667,871	04/01/2005	
04-21P1	INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDES	US	60/630,786	11/23/2004	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0939**

04-21US	INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDES	US	11/267,845	11/04/2005	
04-22P1	INTRANASAL ADMINISTRATION OF NATRIURETIC AND VASODILATOR PEPTIDES	US	60/637,961	12/21/2004	
05-02AU	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Australia	2006257792	12/06/2007	
05-02CA	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Canada	2,611,836	12/11/2007	
05-02EP	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Europe	06773192.7	01/11/2008	
05-02IN	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	India	186/DELNP/2008	01/07/2008	
05-02MX	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Mexico	MX/a/2007/015819	12/13/2007	
05-02NZ	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	New Zealand	564131	11/30/2007	
05-02P1	TRANSMUCOSAL DELIVERY OF MOLECULES CONJUGATED WITH WATER-SOLUBLE POLYMERS IN THE PRESENCE OF PERMEATION ENHANCERS	US	60/689,869	06/13/2005	
05-02PCT	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	PCT	PCT/2006/023220	06/13/2006	
05-02SG	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	Singapore	200718025-0	11/23/2007	
05-02US	TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES	US	11/917,340	12/12/2007	
05-03P1	COMPOUNDS MODIFIED WITH LOW MOLECULAR-WEIGHT POLY (ETHYLENE GLYCOL) AND USES THEREOF	US	60/690,842	06/14/2005	
05-04AU	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Australia	2006269251	01/09/2008	
05-04CA	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Canada		01/08/2008	
05-04CN	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	China	200680033237.3	03/11/2008	
05-04EP	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	EPO	06786757.2	01/31/2008	
05-04IL	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Israel	188448	12/27/2007	
05-04IN	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	India		01/07/2008	
05-04JP	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Japan	2008-521491	01/07/2008	
05-04KR	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Korea	10-2008-7003354	02/11/2008	
05-04MX	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Mexico	MX/a/2008/000600	01/11/2008	
05-04NO	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Norway	20080713	02/11/2008	
05-04NZ	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	New Zealand	564984	01/09/2008	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0940**

05-04P1	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	US	60/698,052	07/11/2005	
05-04PCT	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	PCT	PCT/US2006/026707	07/10/2006	
05-04SG	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	Singapore	200800148-9	01/08/2008	
05-04US	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	US	11/995,315	01/10/2008	
05-04ZA	FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY	South Africa	2008/00285	01/09/2008	
05-05P1	STABLE PYY DOSAGE FORMS FOR ENHANCED MUCOSAL DELIVERY	US	60/699,294	07/13/2005	
05-06P1	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION HAVING HIGH CONCENTRATIONS OF MELANOCORTIN-4 RECEPTOR AGONISTS	US	60/702,576	07/25/2005	
05-06PCT	THERAPEUTIC FORMULATION FOR TRANSMUCOSAL ADMINISTRATION OF A MELANOCORTIN-4 RECEPTOR AGONIST	PCT			
05-07AU	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Australia		02/27/2008	
05-07CA	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Canada		01/25/2008	
05-07CN	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	China		01/28/2008	
05-07CON	TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	12/108,452	04/23/2008	
05-07EP	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	EPO	06800560.2	02/26/2008	
05-07IN	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	India	9261/DELNP/2007	11/30/2007	
05-07JP	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Japan	2008-524269	01/16/2008	
05-07KR	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Republic of Korea	10-2008-7004636	02/26/2008	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0941**

05-07MX	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Mexico	MX/a/2008/001352	01/25/2008	
05-07NZ	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	New Zealand	566281	02/27/2008	
05-07P1	TIGHT JUNCTION MODULATOR PEPTIDE PN159 FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/703,291	07/27/2005	
05-07PCT	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	PCT	PCT/US2006/029768	07/27/2006	
05-07SG	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	Singapore	200719086-1	12/28/2007	
05-07US	TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	11/233,239	09/21/2005	
05-07US2	TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS	US	11/997,132	01/28/2008	
05-08P1	PEGYLATION OF TIGHT JUNCTION MODULATOR PEPTIDES	US	60/703,289	07/27/2005	
05-09P1	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION THAT INCREASE MELANOCORTIN-4 RECEPTOR AGONIST BIOAVAILABILITY	US	60/707,667	08/12/2005	
05-09US	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION THAT INCREASE MELANOCORTIN-4 RECEPTOR AGONIST BIOAVAILABILITY	US	11/464,163	08/11/2006	
05-11P1	TIGHT JUNCTION MODULATING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/710,637	08/22/2005	
05-12P1	TIGHT JUNCTION MODULATING LIPIDS FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/722,334	09/30/2005	
05-12US	METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	11/536,937	09/29/2006	
05-15P1	COMBINATION THERAPY FOR TREATING OSTEOPOROSIS BY INTRANASAL DELIVERY OF PTH(1-34) (TERIPARATIDE)	US	60/730,547	10/25/2005	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0942**

05-15US	METHOD FOR TREATING OSTEOPOROSIS BY INTRANASAL DELIVERY OF TERIPARATIDE WITH AN ANTI-RESORPTIVE AGENT	US	11/552,810	10/25/2006	
05-19AU	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Australia			
05-19CA	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Canada		04/16/2008	
05-19CN	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	China		06/19/2008	
05-19EP	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	EPO	06826368.0	04/15/2008	
05-19IL	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Israel	190838	04/14/2008	
05-19IN	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	India		04/17/2008	
05-19JP	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Japan		04/15/2008	
05-19KR	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Republic of Korea	10-2008-7011970	05/19/2008	
05-19MX	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Mexico	MX/a/2008/004980	04/17/2008	
05-19NZ	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	New Zealand	568357	05/16/2008	
05-19P1	INTRANASAL ADMINISTRATION OF INSULIN	US	60/728,877	10/20/2005	
05-19PCT	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	PCT	PCT/US2006/041081	10/20/2006	
05-19SG	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	Singapore	200802830-0	04/14/2008	
05-19ZA	COMPOSITIONS AND USE FOR INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	South Africa	2008/04287	05/19/2008	
05-22P1	TRANSMUCOSAL DELIVERY OF MELANOCORTIN-4 RECEPTOR AGONIST PEPTIDE CONJUGATED WITH WATER-SOLUBLE POLYMERS IN THE PRESENCE OF PERMEATION ENHANCERS	US	60/748,946	12/09/2005	
05-23P1	COMPOSITION FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE	US	60/738,264	11/17/2005	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0943**



05-24P1	METHOD OF MODULATING HEMATOPOIETIC STEM CELLS AND TREATING HEMATOLOGIC DISEASES USING INTRANASAL PARATHYROID HORMONE	US	60/738,224	11/18/2005	
05-24US	METHOD OF MODULATING HEMATOPOIETIC STEM CELLS AND TREATING HEMATOLOGIC DISEASES USING INTRANASAL PARATHYROID HORMONE	US	11/559,276	11/13/2006	
05-32P1	TIGHT JUNCTION MODULATING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/750,886	12/16/2005	
05-32US	TIGHT JUNCTION MODULATING PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	11/611,289	12/15/2006	
05-33P1	INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS	US	60/751,598	12/19/2005	
05-33US	INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS	US	11/613,109	12/19/2006	
05-34P1	ENHANCED MUCOSAL ADMINISTRATION OF NEUROPROTECTIVE PEPTIDES	US	60/753,968	12/23/2005	
05-34US	ENHANCED MUCOSAL ADMINISTRATION OF NEUROPROTECTIVE PEPTIDES	US	11/614,534	12/21/2006	
06-01P1	TIGHT JUNCTION MODULATING LIPIDS FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/760,815	01/20/2006	
06-03P1	METHOD OF INCREASING BIOAVAILABILITY OF A DRUG USING PEGYLATED TIGHT JUNCTION MODULATOR PEPTIDES	US	60/772,435	02/10/2006	
06-04P1	A METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/772,311	02/10/2006	
06-07P1	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/778,724	03/03/2006	
06-08P1	THERAPEUTIC FORMULATIONS FOR TRANSMUCOSAL ADMINISTRATION HAVING HIGH CONCENTRATIONS OF AMPA RECEPTOR REGULATING COMPOUNDS	US	60/778,681	03/03/2006	
06-09P1	A METHOD FOR IMPROVED PEPTIDE IN-USE STABILITY	US	60/796,273	04/27/2006	
06-12P1	COMPOSITIONS AND METHODS FOR ENHANCED CALORIC INTAKE REDUCTION AND METHODS FOR TREATING AND PREVENTING OBESITY	US	60/871,092	12/20/2006	
06-13E1	INTRANASAL ADMINISTRATION OF A RAPID ACTING INSULIN FORMULATION	US	11/456,176	07/10/2006	
06-13P1	INTRANASAL ADMINISTRATION OF A RAPID ACTING INSULIN FORMULATION	US	60/806,904	07/10/2006	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0944**

06-19P1	PTH FORMULATIONS FOR INTRANASAL DELIVERY	US	60/806,760	07/07/2006	
06-19US	PTH FORMULATIONS FOR INTRANASAL DELIVERY	US	11/774,501	07/06/2007	
06-24P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/804,165	06/07/2006	
06-26P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/806,230	06/29/2006	
06-26P2	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/807,055	07/11/2006	
06-26P3	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/825,090	09/08/2006	
06-26PCT	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	PCT	PCT/US2007/060517	01/12/2007	
06-28P1	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/821,525	08/04/2006	
06-28P2	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/825,876	09/15/2006	
06-28P3	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/868,703	12/05/2006	
06-28P4	INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN	US	60/894,130	03/09/2007	
06-28PCT	COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF	PCT	PCT/US2007/67007	04/19/2007	
06-29P1	PTH FORMULATIONS AND METHODS OF USE	US	60/871,633	12/22/2006	
06-29P2	VISCOSITY ENHANCED PTH FORMULATIONS AND IONIC POLYMER-PTH SUSPENSIONS AND METHODS OF USE	US	60/945,867	06/22/2007	
06-29P3	IONIC POLYMER-PTH SUSPENSIONS WITHIN A REVERSIBLE GEL MATRIX AND METHODS OF USE	US	60/947,362	06/29/2007	
07-05P1	PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES	US	60/891,204	02/22/2007	
07-05P2	PHARMACEUTICAL FORMULATIONS FOR INTRANASAL DELIVERY OF GLP-1 DERIVATIVES	US	60/944,397	06/15/2007	
07-05P3	FORMULATIONS FOR DELIVERY OF GLP-1 DERIVATIVES AND USES THEREOF	US	61/015,036	12/19/2007	
07-06P1	METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/909,333	03/30/2007	
07-07P1	GLP-1 ANALOGS, DERIVATIVES AND USE THEREOF	US	60/911,249	04/11/2007	
07-07US	PHARMACEUTICAL FORMULATIONS FOR INTRANASAL DELIVERY OF GLP-1 ANALOGS, DERIVATIVES AND USE THEREOF	US	11/841,697	08/20/2007	
07-08P1	COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS	US	60/910,388	04/05/2007	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0945**

07-09P1	STABLE PEPTIDES AND PROTEINS AND METHODS FOR REDUCING DEAMIDATION	US	60/914,247	04/26/2007	
07-11P1	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND METHODS OF USE	US	60/909,757	04/03/2007	
07-13P1	INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR TREATMENT OF AUTISM	US	60/942,607	06/07/2007	
07-14P1	ULTRA-RAPID ACTING INTRANASAL MONOMER/DIMER STABILIZED INSULIN FORMULATIONS	US	60/942,981	06/08/2007	
07-14P2	PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP FOR ULTRA-RAPID ACTING INTRANASAL INSULIN FORMULATIONS	US	60/955,306	08/10/2007	
07-14P3	INSULIN DOSAGE FORM FOR ULTRA-RAPID ACTING INTRANASAL INSULIN FORMULATIONS	US	61/016,383	12/21/2007	
07-14US	INSULIN DOSAGE FORM FOR ULTRA-RAPID ACTING INTRANASAL INSULIN FORMULATIONS	US	11/841,688	08/20/2007	
07-18P1	FORMULATIONS FOR INTRANASAL DELIVERY OF DIAZEPAM	US	60/977,848	10/05/2007	
07-18P2	FORMULATIONS FOR INTRANASAL DELIVERY OF DIAZEPAM AND USE THEREOF	US	60/982,680	10/25/2007	
07-18P3	MULTI-COMPONENT FORMULATIONS FOR INTRANASAL DELIVERY OF DIAZEPAM AND USE THEREOF	US	60/985,918	11/06/2007	
07-18P4	MULTI-COMPONENT DIAZEPAM FORMULATIONS AND USES THEREOF	US	60/989,370	11/20/2007	
07-18P5	MULTI-COMPONENT FORMULATIONS FOR ADMINISTRATION OF DIAZEPAM AND USES THEREOF	US	61/020,668	01/11/2008	
07-20P1	POLYMER DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF	US	60/971,488	09/11/2007	
07-25P1	MUCOSAL DELIVERY OF FACTOR IX AND USES THEREOF	US	60/988,036	11/14/2007	
08-01P1	LIPOPHILIC AMINES AND USES THEREOF	US	61/057,153	05/29/2008	
08-05P1	STABLE PEPTIDES AND PROTEINS AND METHODS FOR REDUCING DEAMIDATION	US	60/047,136	04/23/2008	
81-01CA	METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME	Canada	401,775	04/27/1982	1,183,778
81-01PCT	METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME	PCT	PCT/US82/00546	04/27/1982	
81-01US	METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/258,308	04/28/1981	4,464,378

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0946**

84-01AT	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Austria	85905471	10/22/1985	E75400
84-01AU2	ANTI-NAUSEA AND ANTI-EMETIC AGENTS	Australia	15061/88	04/21/1988	596741
84-01BE	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Belgium	85905471.0	10/22/1985	0201537
84-01CA	METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Canada	493629	10/23/1985	1265056
84-01CA2	METHODS OF ADMINISTERING ANTIHISTAMINES, ANTINAUSEA AND ANTIEMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Canada	565963	05/05/1988	1309023
84-01CH	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Switzerland and Liechtens	85905471	10/22/1985	201537
84-01CIP	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/671,694	11/15/1984	
84-01CIP/AU	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Australia	50638/85	10/22/1985	
84-01CIP/BR	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Brazil	P18507008	10/22/1985	
84-01CIP2	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/787,617	10/15/1985	4,624,965
84-01CIP2/DIV	NOVEL METHOD OF ADMINISTERING MECLIZINE TYPE PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/897,863	08/19/1986	4,729,997

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0947**

84-01CIP2DIVCIP	NOVEL METHOD OF ADMINISTERING ANTIHISTAMINES, ANTINAUSEA AND ANTIEMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	07/042,386	04/24/1987	4,749,700
84-01DE	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Germany	85905471.0	10/22/1985	P3585952.0
84-01EP	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	EPO	85905471	10/22/1985	201537
84-01FR	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	France	85905471	10/22/1985	201537
84-01GB	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	United Kingdom	85905471.0	10/22/1985	201537
84-01IT	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Italy	85905471.0	10/22/1985	201537
84-01JP	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Japan	504814/85	10/22/1985	1993603
84-01LU	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Luxembourg	85905471	10/22/1985	201537
84-01NL	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Netherlands	85905471	10/22/1985	201537
84-01P1	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/663,894	10/23/1984	
84-01PCT	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	PCT	PCT/US85/02071	10/22/1985	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0948**

84-01SE	NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME	Sweden	85905471	10/22/1985	201537
84-02CIP	NOVEL METHOD OF ADMINISTERING TESTOSTERONE AND NOVEL DOSAGE FORMS CONTAINING SAME	US	06/679,553	12/07/1984	
92-01AT	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Austria	93920574.6	03/11/1993	630236
92-01AU	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Australia	38044/93	03/11/1993	680408
92-01BE	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Belgium	93920574.6	03/11/1993	630236
92-01CA	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Canada	N/A	03/11/1993	
92-01CH	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Switzerland and Liechtens	93920574.6	03/11/1993	630236
92-01DE	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Germany	93920574.6	03/11/1993	630236
92-01DK	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Denmark	93920574.6	03/11/1993	630236
92-01EP	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	EPO	93920574.6	03/11/1993	630236
92-01ES	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Spain	93920574.6	03/11/1993	630236
92-01FR	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	France	93920574.6	03/11/1993	630236
92-01GB	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	United Kingdom	93920574.6	03/11/1993	630236
92-01GR	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Greece	93920574.6	03/11/1993	630236
92-01IE	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Ireland	93920574.6	03/11/1993	630236
92-01JP	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Japan	5-516624	03/11/1993	2617273
92-01LU	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Luxembourg	93920574.6	03/11/1993	630236
92-01MC	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Monaco	93920574.6	03/11/1993	630236
92-01NL	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Netherlands	93920574.6	03/11/1993	630236
92-01PT	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Portugal	93920574.6	03/11/1993	630236
92-01SE	SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	Sweden	93920574.6	03/11/1993	630236
96-02AT	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Austria	97944550.9	09/29/1997	
96-02AU	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Australia	46019/97	09/29/1997	714913
96-02BE	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Belgium	97944550.9	09/29/1997	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0949**

96-02CA	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Canada	2,266,898	09/29/1997	
96-02EP	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	EPO	97944550.9	04/26/1999	
96-02JP	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Japan	10-515992	09/29/1997	
96-02P	DOXYLAMINE SUCCINATE FORMULATION DEVELOPMENT FIRST LINE OF FORMULATIONS FOR HUMAN STUDIES	US	60/026,811	09/27/1996	
96-02PCT	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	PCT	PCT/US97/17475	09/29/1997	
96-02US	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	US	08/939,279	09/29/1997	5,874,450
96-03AU	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	Australia	54294/98	11/04/1997	725498
96-03CA	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	CANADA	2,271,724	11/04/1997	
96-03EP	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	EPC	97948175.1	11/04/1997	
96-03JP	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	Japan	10-522637	05/12/1999	
96-03PCT	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	PCT	PCT/US97/20115	11/04/1997	
96-03US	METHOD FOR INCREASING THE SOLUBILITY OF CLEMASTINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	US	08/748,356	11/13/1996	5,770,618
97-01AT	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Austria	98946945.7	09/11/1998	
97-01AU	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Australia	93850/98	09/11/1998	742878
97-01BE	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Belgium	98946945.7	09/11/1998	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0950**

97-01CA	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Canada	2,303,132	09/11/1998	2,303,132
97-01CH	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Switzerland and Liechtens	98946945.7	09/11/1998	
97-01DE	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Germany	98946945.7	09/11/1998	
97-01DK	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Denmark	98946945.7	09/11/1998	
97-01EP	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	EPO	98 946 945.7-2123	09/11/1998	
97-01ES	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Spain	98946945.7	09/11/1998	
97-01FI	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Finland	98946945.7	09/11/1998	
97-01FR	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	France	98946945.7	09/11/1998	
97-01GB	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	United Kingdom	98946945.7	09/11/1998	
97-01GR	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Greece	98946945.7	09/11/1998	
97-01IE	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Ireland	98946945.7	09/11/1998	
97-01IT	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Italy	98946945.7	09/11/1998	
97-01JP	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Japan	2000-510441	09/11/1998	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0951**



97-01LU	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Luxembourg	98946945.7	09/11/1998	
97-01MC	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Monoco	98946945.7	09/11/1998	
97-01NL	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Netherlands	98946945.7	09/11/1998	
97-01P	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	US	60/058,651	09/11/1997	
97-01PCT	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	PCT	PCT/US98/18953	09/11/1998	
97-01PT	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Portugal	98946945.7	09/11/1998	
97-01SE	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	Sweden	98946945.7	09/11/1998	
97-01US2	INTRANASAL FORMULATIONS CONTAINING SCOPOLAMINE AND METHOD OF TREATING MOTION SICKNESS	US	09/486,839	03/01/2000	
98-01P1	NASAL DELIVERY OF SILDENAFIL CITRATE	US	60/090,941	06/26/1998	
98-01PCT	NASAL DELIVERY OF SILDENAFIL CITRATE	PCT	PCT/US99/14352	06/24/1999	
98-02P1	METHODS OF PREVENTING AND TREATING MOTION SICKNESS	US	60/091,114	06/29/1998	
98-02PCT	METHODS OF PREVENTING AND TREATING MOTION SICKNESS	PCT	PCT/US99/14657	06/29/1999	
98-03AT	NASAL DELIVERY OF APOMORPHINE	Austria	914639	02/18/2000	
98-03AU	NASAL DELIVERY OF APOMORPHINE	Australia	36,002/00	02/18/2000	
98-03BE	NASAL DELIVERY OF APOMORPHINE	Belgium	914639	02/18/2000	
98-03BR	NASAL DELIVERY OF APOMORPHINE	Brazil	PI0012080.4	02/18/2000	
98-03BZ	NASAL DELIVERY OF APOMORPHINE	Belize			
98-03CA	NASAL DELIVERY OF APOMORPHINE	Canada	2,376,921	02/18/2000	
98-03CIP2	NASAL DELIVERY OF APOMORPHINE FOR YIELDING ENHANCED NASAL ABSORPTION	US	09,882,746	06/11/2001	
98-03CIP3	NASAL DELIVERY OF APOMORPHINE IN COMBINATION WITH GLYCOL DERIVATIVES	US	09/665,500	09/19/2000	
98-03CIP3/PCT	NASAL DELIVERY OF APOMORPHINE IN COMBINATION WITH GLYCOL DERIVATIVES	PCT	PCT/US01/29437	09/19/2001	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0952**

98-03CO	NASAL DELIVERY OF APOMORPHINE	Colombia			
98-03CON1	NASAL DELIVERY OF APOMORPHINE	US	10/062,020	01/31/2002	
98-03CON2	NASAL DELIVERY OF APOMORPHINE	US	10/062,021	01/31/2002	6,740,660
98-03CON3	NASAL DELIVERY OF APOMORPHINE	US	10/062,290	01/31/2002	
98-03CON5	NASAL DELIVERY OF APOMORPHINE IN COMBINATION WITH GLYCOL DERIVATIVES	US	10/701,956	11/05/2003	
98-03CON6	NASAL DELIVERY OF APOMORPHINE	US	10/830,251	04/21/2004	
98-03CON7	NASAL DELIVERY OF APOMORPHINE	US	10/830,250	04/21/2004	
98-03CON8	NASAL DELIVERY OF APOMORPHINE	US	10/830,255	04/21/2004	
98-03CON9	NASAL DELIVERY OF APOMORPHINE	US	10/830,309	04/21/2004	
98-03CR	NASAL DELIVERY OF APOMORPHINE	Costa Rica	6521	12/04/2001	
98-03CY	NASAL DELIVERY OF APOMORPHINE	Cyprus	914639	02/18/2000	
98-03DE	NASAL DELIVERY OF APOMORPHINE	Germany	914639	02/18/2000	
98-03DK	NASAL DELIVERY OF APOMORPHINE	Denmark	914639	02/18/2000	
98-03EC	NASAL DELIVERY OF APOMORPHINE	Ecuador			
98-03EP	NASAL DELIVERY OF APOMORPHINE	EPO	00914639.0-2123	02/18/2000	
98-03EPDIV	NASAL DELIVERY OF APOMORPHINE	EPO	04028289.9	11/30/2004	
98-03FI	NASAL DELIVERY OF APOMORPHINE	Finland	914639	02/18/2000	
98-03FR	NASAL DELIVERY OF APOMORPHINE	France	914639	02/18/2000	
98-03GB	NASAL DELIVERY OF APOMORPHINE	United Kingdom	914639	02/18/2000	
98-03GR	NASAL DELIVERY OF APOMORPHINE	Ireland	914639	02/18/2000	
98-03JP	NASAL DELIVERY OF APOMORPHINE	Japan	2001-502842	02/18/2000	
98-03KR	NASAL DELIVERY OF APOMORPHINE	Republic of Korea	2001-7016072	02/18/2000	
98-03MX	NASAL DELIVERY OF APOMORPHINE	Mexico	2001-012877	02/18/2000	
98-03NZ	NASAL DELIVERY OF APOMORPHINE	New Zealand	515782	02/18/2000	
98-03NZ2	NASAL DELIVERY OF APOMORPHINE	New Zealand	529954	12/04/2003	
98-03P1	NASAL DELIVERY OF APOMORPHINE	US	60/096,545	08/14/1998	
98-03PCT	NASAL DELIVERY OF APOMORPHINE	PCT	PCT/US00/04268	02/18/2000	
98-03US	NASAL DELIVERY OF APOMORPHINE	US	09/334,304	06/16/1999	6,436,950
98-04P1	NASAL DELIVERY OF XYLITOL	US	60/106,388	10/30/1998	
99-01AL	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Albania	932722.2	05/23/2000	
99-01AT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Austria	932722.2	05/23/2000	
99-01AU	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Australia	50405/00	05/23/2000	775,112
99-01BE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Belgium	932722.2	05/23/2000	
99-01BR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Brazil	PI 0012081-2	05/23/2000	
99-01CA	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Canada	2,376,865	12/11/2001	
99-01CH	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Switzerland and Liechtens	932722.2	05/23/2000	
99-01CON	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	US	09/626,942	10/19/2000	6,451,848
99-01CY	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Cyprus	932722.2	05/23/2000	
99-01DE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Germany	932722.2	05/23/2000	
99-01DK	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Denmark	932722.2	05/23/2000	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0953**

99-01EP	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	EPO	00932722.2	05/23/2000	
99-01FI	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Finland	932722.2	05/23/2000	
99-01FR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	France	932722.2	05/23/2000	
99-01GB	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	United Kingdom	932722.2	05/23/2000	
99-01GR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Greece	932722.2	05/23/2000	
99-01IE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Ireland	932722.2	05/23/2000	
99-01IT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Italy	932722.2	05/23/2000	
99-01JP	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Japan	2001-502671	05/23/2000	
99-01KR	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Republic of Korea	2001-7016073	11/13/2001	
99-01LT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Lithuania	932722.2	05/23/2000	
99-01LU	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Luxembourg	932722.2	05/23/2000	
99-01MC	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Monoco	932722.2	05/23/2000	
99-01MX	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Mexico	2001-012882	05/23/2000	
99-01NL	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Netherlands	932722.2	05/23/2000	
99-01NZ	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	New Zealand	515781	05/23/2000	515781
99-01PCT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	PCT	PCT/US00/14150	05/23/2000	
99-01PT	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Portugal	932722.2	05/23/2000	
99-01RO	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Romania	932722.2	05/23/2000	
99-01SE	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Sweden	932722.2	05/23/2000	
99-01SI	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	Slovenia	932722.2	05/23/2000	
99-01US	COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE	US	09/334,344	06/16/1999	6,225,343
99-02AT	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Austria	A9104/2000	05/23/2000	
99-02AU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Australia	51561/00	05/23/2000	774,175
99-02BA	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Bosnia and Herzegovina	BAP01950A	05/23/2000	
99-02BR	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Brazil	PI 0012082-0	05/23/2000	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0954**

99-02BU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Bulgaria	106221	05/23/2000	
99-02CA	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Canada	2,374,844	05/23/2000	2,374,877
99-02CH	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Switzerland and Liechtens	2283/01	05/23/2000	
99-02CZ	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Czech Republic	PV 2001-4399	05/23/2000	
99-02DE	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Germany	10084709.9	05/23/2000	
99-02DIV	METHODS COMPRISING INTRANASAL MORPHINE	US	09/594,916	06/15/2000	6,677,346
99-02DIV2	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	US			
99-02DK	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Denmark	PA200101859	05/23/2000	
99-02EE1	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Estonia	0677/01PC	05/23/2000	
99-02EE2	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Estonia	P200300555		
99-02EP1	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	EPO	00936212.0	05/23/2000	
99-02EP2	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	EPO	04001252.8	05/23/2000	
99-02ES	PHARMACEUTICAL FORMULATIONS CONTAINING INTRANASAL MORPHINE	Spain	P200150086	05/23/2000	
99-02FI	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Finland	20012462	05/23/2000	20012462
99-02GB	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	United Kingdom	0128383.7	05/23/2000	2367005
99-02HK	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Hong Kong		08/02/2004	
99-02HK1	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Hong Kong		08/02/2004	
99-02HK2	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Hong Kong	04105666.8	08/02/2004	
99-02HR	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Croatia	P20010926A	05/23/2000	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0955**

99-02HU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Hungary	P0201856	05/23/2000	
99-02IS	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Iceland	6202	05/23/2000	
99-02JP	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Japan	2001-502839	05/23/2000	
99-02KR	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Republic of Korea	2001-7016009	05/23/2000	
99-02LT	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Lithuania	2001-119	05/23/2000	4976
99-02LU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Luxembourg	90859	05/23/2000	90859
99-02LV	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Latvia	P-01-169	05/23/2000	12859
99-02MK1	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Macedonia	P-20010120	05/23/2000	
99-02MK2	USE OF MORPHINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR MANUFACTURE OF A NASAL PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF PAIN	Macedonia	P-20030381	11/13/2003	
99-02MK3	USE OF A BUFFER FOR MANUFACTURE OF A NASAL FORMULATION FOR INCREASE SOLUBILITY OF MORPHINE	Macedonia	P-20030382	11/13/2003	
99-02MX	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Mexico	2001-012879	05/23/2000	
99-02NO	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Norway	20015931	05/23/2000	
99-02NZ	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	New Zealand	515783	05/23/2000	515783
99-02PCT	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	PCT	PCT/US00/14157	05/23/2000	
99-02PL	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Poland	P 352556	05/23/2000	
99-02PT	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Portugal	WO 00/76506	05/23/2000	
99-02RO	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Romania	2001-01346	05/23/2000	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0956**

99-02SE	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Sweden	0104203-5	05/23/2000	
99-02SI	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Slovenia	P-200020030	05/23/2000	20850
99-02SK	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Slovak Republic	PV1817-2001S	05/23/2000	
99-02TR	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Turkey	2001/03613	05/23/2000	
99-02US	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	US	09/334,537	06/16/1999	
99-02YU	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Yugoslavia	N/A	05/23/2000	
99-03PCT	METHODS AND COMPOSITIONS FOR TREATING BREAKTHROUGH PAIN	PCT	PCT/US00/14663	05/26/2000	
99-03US	METHODS AND COMPOSITIONS FOR TREATING BREAKTHROUGH PAIN	US	09/334,303	06/16/1999	
99-04DIV	METHOD FOR INCREASING THE SOLUBILITY OF MORPHINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	US	09/627,598	07/28/2000	
99-04PCT	METHOD FOR INCREASING THE SOLUBILITY OF MORPHINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	PCT	PCT/US00/14662	05/26/2000	
99-04US	METHOD FOR INCREASING THE SOLUBILITY OF MORPHINE AND PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM	US	09/334,536	06/16/1999	
99-05P1	NASAL ADMINISTRATION OF BUTORPHANOL	US	60/166,841	11/22/1999	
99-05P2	NASAL ADMINISTRATION OF BUTORPHANOL	US	60/190,982	03/12/2000	
99-05US	PHARMACEUTICAL COMPOSITIONS FOR NASALLY ADMINISTERED ANALGESICS SUCH AS BUTORPHANOL	US	09/644,174	08/23/2000	
99-06P1	METERING DEVICE	US	60/167,295	11/24/1999	
99-06US	CHILD-RESISTANT SAFETY CLOSURE	US	09/642,364	08/21/2000	
NPCI-0068 719- 6CIP/PCT/EP O/DENMAR K	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Denmark	97944550.9	09/29/1997	
NPCI-0069 719- 6CIP/PCT/EP O/FINLAND	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Finland	97944550.9	09/29/1997	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0957**

NPCI-0070 719- 6CIP/PCT/EP O/FRANCE	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	France	97944550.9	09/29/1997	
NPCI-0071 719- 6CIP/PCT/EP O/GREATBR ITAIN	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	United Kingdom	97944550.9	09/29/1997	
NPCI-0072 719- 6CIP/PCT/EP O/GERMAN Y	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Germany	97944550.9	09/29/1997	
NPCI-0073 719- 6CIP/PCT/EP O/GREECE	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Greece	97944550.9	09/29/1997	
NPCI-0074 719- 6CIP/PCT/EP O/IRELAND	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Ireland	97944550.9	09/29/1997	
NPCI-0075 719- 6CIP/PCT/EP C/ITALY	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Italy	97944550.9	09/29/1997	
NPCI-0076 719- 6CIP/PCT/EP O/LUXEMB OURG	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Luxembourg	97944550.9	09/29/1997	
NPCI-0077 719- 6CIP/PCT/EP O/MONACO	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Monoco	97944550.9	09/29/1997	
NPCI-0078 719- 6CIP/PCT/EP O/NETHERL ANDS	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Netherlands	97944550.9	09/29/1997	
NPCI-0079 719- 6CIP/PCT/EP O/PORTUGA L	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Portugal	97944550.9	09/29/1997	
NPCI-0080 719- 6CIP/PCT/EP O/SPAIN	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Spain	97944550.9	09/29/1997	
NPCI-0081 719- 6CIP/PCT/EP O/SWEDEN	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Sweden	97944550.9	09/29/1997	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0958**

NPCI-0082 719- 6CIP/PCT/EP O/SWITZER LAND	INTRANASAL FORMULATIONS FOR PROMOTING SLEEP AND METHOD OF USING THE SAME	Switzerland and Liechtens	97944550.9	09/29/1997	
NPCI-0202 719-127	NASAL DELIVERY OF APOMORPHINE	Greece	914639	02/18/2000	
NPCI-0204 719-127	NASAL DELIVERY OF APOMORPHINE	Italy	914639	02/18/2000	
NPCI-0205 719-127	NASAL DELIVERY OF APOMORPHINE	Luxembourg	914639	02/18/2000	
NPCI-0206 719-127	NASAL DELIVERY OF APOMORPHINE	Monoco	914639	02/18/2000	
NPCI-0207 719-127	NASAL DELIVERY OF APOMORPHINE	Netherlands	914639	02/18/2000	
NPCI-0208 719-127	NASAL DELIVERY OF APOMORPHINE	Portugal	914639	02/18/2000	
NPCI-0209 719-127	NASAL DELIVERY OF APOMORPHINE	Spain	914639	02/18/2000	
NPCI-0210 719-127	NASAL DELIVERY OF APOMORPHINE	Sweden	914639	02/18/2000	
NPCI-0211 719-127	NASAL DELIVERY OF APOMORPHINE	Switzerland and Liechtens	914639	02/18/2000	
NPCI-0212 719-127	NASAL DELIVERY OF APOMORPHINE	Albania	914639	02/18/2000	
NPCI-0213 719-127	NASAL DELIVERY OF APOMORPHINE	Lithuania	914639	02/18/2000	
NPCI-0214 719-127	NASAL DELIVERY OF APOMORPHINE	Latvia	914639	02/18/2000	
NPCI-0215 719-127	NASAL DELIVERY OF APOMORPHINE	Romania	914639	02/18/2000	
NPCI-0216 719-127	NASAL DELIVERY OF APOMORPHINE	Slovenia	914639	02/18/2000	
NPCI-0231 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Austria	936212	05/23/2000	
NPCI-0232 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Belgium	936212	05/23/2000	
NPCI-0233 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Cyprus	936212	05/23/2000	
NPCI-0234 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Denmark	936212	05/23/2000	
NPCI-0235 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Finland	936212	05/23/2000	
NPCI-0236 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	France	936212	05/23/2000	
NPCI-0237 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	United Kingdom	936212	05/23/2000	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0959**



NPCI-0238 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Germany	936212	05/23/2000	
NPCI-0239 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Greece	936212	05/23/2000	
NPCI-0240 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Ireland	936212	05/23/2000	
NPCI-0241 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Italy	936212	05/23/2000	
NPCI-0242 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Luxembourg	936212	05/23/2000	
NPCI-0243 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Monoco	936212	05/23/2000	
NPCI-0244 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Netherlands	936212	05/23/2000	
NPCI-0245 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Portugal	936212	05/23/2000	
NPCI-0246 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Spain	936212	05/23/2000	
NPCI-0247 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Sweden	936212	05/23/2000	
NPCI-0248 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Switzerland and Liechtens	936212	05/23/2000	
NPCI-0249 NPCI-0249	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Albania	936212	05/23/2000	
NPCI-0250 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Lithuania	936212	05/23/2000	
NPCI-0251 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Latvia	936212	05/23/2000	
NPCI-0252 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Romania	936212	05/23/2000	
NPCI-0253 719-163	PHARMACEUTICAL FORMULATIONS AND METHODS COMPRISING INTRANASAL MORPHINE	Slovenia	936212	05/23/2000	
NPCI-0281 719-185	STA-T Trademark	US	76/025,952	04/14/2000	
NPCI- 0281TTAB 719-185	STA-T Trademark	US	91150896	12/21/2001	

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 004121 FRAME: 0960**

NPCI- 0281TTAB1 719-185	STA-T Trademark	US	91150896	12/21/2001	
-------------------------------	-----------------	----	----------	------------	--

ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE